盟科药业(688373) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥14,473,608.59, representing a year-over-year increase of 163.64%[2] - The net profit attributable to shareholders was -¥66,026,734.90, with no applicable year-over-year comparison due to the negative result[2] - The company experienced a year-to-date net profit attributable to shareholders of -¥173,774,505.72, with no applicable year-over-year comparison due to the negative result[2] - The net loss for the first three quarters of 2022 was ¥173,774,505.72, compared to a net loss of ¥125,500,042.16 in the same period of 2021, representing an increase in losses of approximately 38.5%[18] - The company reported a basic and diluted earnings per share of -¥0.31 for the first three quarters of 2022, compared to -¥0.24 in the same period of 2021[19] Research and Development - Research and development (R&D) expenses totaled ¥49,392,997.52, an increase of 67.75% compared to the same period last year[3] - The ratio of R&D expenses to operating revenue was 341.26%, indicating a decrease of 195.08 percentage points year-over-year[3] - Research and development expenses amounted to ¥114,940,211.45, up from ¥86,620,479.71 in the same period last year, indicating a year-over-year increase of about 32.6%[17] - The company is focusing on expanding its market presence and enhancing its product offerings through increased R&D investment[7] - The company plans to continue focusing on R&D and market expansion strategies to improve future performance and mitigate losses[21] Assets and Liabilities - Total assets reached ¥1,468,974,576.51, reflecting a growth of 126.51% compared to the end of the previous year[3] - Total current assets as of September 30, 2022, amounted to RMB 1,340,580,334.75, an increase from RMB 509,587,048.89 in 2021[11] - Total assets reached RMB 1,468,974,576.51, compared to RMB 648,539,320.38 in the previous year[13] - The total liabilities as of the end of the reporting period were ¥213,414,694.15, slightly up from ¥210,166,885.46 at the end of the previous year[18] - The total equity attributable to shareholders increased to ¥1,255,559,882.36 from ¥438,372,434.92, showing a substantial growth in shareholder equity[18] Cash Flow - The company reported a net cash flow from operating activities of -¥178,919,707.70 for the year-to-date period[2] - The total cash flow from operating activities for the first three quarters of 2022 was not detailed in the provided content, indicating a need for further analysis[21] - In the first three quarters of 2022, the cash inflow from operating activities was CNY 47,059,687.72, compared to CNY 36,924,897.56 in the same period of 2021, representing an increase of approximately 27.6%[22] - The net cash flow from operating activities for the first three quarters of 2022 was -CNY 178,919,707.70, worsening from -CNY 126,592,211.55 in the first three quarters of 2021[22] - The cash inflow from investment activities in the first three quarters of 2022 was CNY 842,619,850.23, a decrease of 47.2% from CNY 1,591,970,777.97 in the same period of 2021[22] Shareholder Information - Total number of common shareholders at the end of the reporting period was 26,442[9] - Genie Pharma held 71,572,817 shares, representing 10.92% of total shares[9] - The company had a total of 128,523,904 restricted shares, accounting for 19.62% of the total share capital[10] Inventory and Costs - The company reported a significant increase in inventory, which rose to RMB 17,924,385.01 from RMB 11,008,530.01[11] - Total operating costs for the first three quarters of 2022 were ¥224,307,692.69, compared to ¥168,395,558.64 in the previous year, reflecting a year-over-year increase of approximately 33.2%[17]